JP2000502257A - ヘテロフィル適合化家禽用ワクチン - Google Patents
ヘテロフィル適合化家禽用ワクチンInfo
- Publication number
- JP2000502257A JP2000502257A JP9523045A JP52304597A JP2000502257A JP 2000502257 A JP2000502257 A JP 2000502257A JP 9523045 A JP9523045 A JP 9523045A JP 52304597 A JP52304597 A JP 52304597A JP 2000502257 A JP2000502257 A JP 2000502257A
- Authority
- JP
- Japan
- Prior art keywords
- poultry
- strain
- microorganism
- heterofil
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 244000144977 poultry Species 0.000 title claims abstract description 67
- 229960005486 vaccine Drugs 0.000 title claims abstract description 53
- 244000005700 microbiome Species 0.000 claims abstract description 74
- 238000000034 method Methods 0.000 claims abstract description 40
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- 235000013601 eggs Nutrition 0.000 claims description 49
- 241000607142 Salmonella Species 0.000 claims description 20
- 238000002255 vaccination Methods 0.000 claims description 17
- 239000003242 anti bacterial agent Substances 0.000 claims description 15
- 229940088710 antibiotic agent Drugs 0.000 claims description 13
- 102000009016 Cholera Toxin Human genes 0.000 claims description 11
- 108010049048 Cholera Toxin Proteins 0.000 claims description 11
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 claims description 8
- 239000004475 Arginine Substances 0.000 claims description 7
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 7
- 238000005406 washing Methods 0.000 claims description 7
- 230000003115 biocidal effect Effects 0.000 claims description 6
- 229930182566 Gentamicin Natural products 0.000 claims description 5
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 5
- 229960002518 gentamicin Drugs 0.000 claims description 5
- 229930027917 kanamycin Natural products 0.000 claims description 5
- 229960000318 kanamycin Drugs 0.000 claims description 5
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 5
- 229930182823 kanamycin A Natural products 0.000 claims description 5
- 230000002238 attenuated effect Effects 0.000 claims description 3
- 229940124590 live attenuated vaccine Drugs 0.000 claims description 3
- 229940023012 live-attenuated vaccine Drugs 0.000 claims description 3
- 238000002955 isolation Methods 0.000 claims description 2
- 230000005540 biological transmission Effects 0.000 abstract description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
- 206010039438 Salmonella Infections Diseases 0.000 abstract description 8
- 206010039447 salmonellosis Diseases 0.000 abstract description 8
- 230000000813 microbial effect Effects 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 3
- 230000036541 health Effects 0.000 abstract description 2
- 235000013594 poultry meat Nutrition 0.000 description 34
- 210000003608 fece Anatomy 0.000 description 30
- 230000029142 excretion Effects 0.000 description 20
- 238000002474 experimental method Methods 0.000 description 19
- 230000006978 adaptation Effects 0.000 description 17
- 208000015181 infectious disease Diseases 0.000 description 14
- 239000003651 drinking water Substances 0.000 description 11
- 235000020188 drinking water Nutrition 0.000 description 11
- 230000002550 fecal effect Effects 0.000 description 11
- 230000036039 immunity Effects 0.000 description 10
- 238000011534 incubation Methods 0.000 description 10
- 239000006154 MacConkey agar Substances 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000000243 solution Substances 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 229920001817 Agar Polymers 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 6
- 241000287828 Gallus gallus Species 0.000 description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- 239000008272 agar Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000008188 pellet Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 4
- 235000013330 chicken meat Nutrition 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 230000035622 drinking Effects 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 4
- 229930182490 saponin Natural products 0.000 description 4
- 150000007949 saponins Chemical class 0.000 description 4
- 102000002322 Egg Proteins Human genes 0.000 description 3
- 108010000912 Egg Proteins Proteins 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 210000003278 egg shell Anatomy 0.000 description 3
- 210000001539 phagocyte Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 241000271566 Aves Species 0.000 description 2
- 241000272201 Columbiformes Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000272458 Numididae Species 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- 230000000721 bacterilogical effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 239000000976 ink Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101001056878 Homo sapiens Squalene monooxygenase Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000288049 Perdix perdix Species 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 208000027954 Poultry disease Diseases 0.000 description 1
- 241000392514 Salmonella enterica subsp. enterica serovar Dublin Species 0.000 description 1
- 241000607132 Salmonella enterica subsp. enterica serovar Gallinarum Species 0.000 description 1
- 241000607683 Salmonella enterica subsp. enterica serovar Pullorum Species 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229960001212 bacterial vaccine Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 229960001506 brilliant green Drugs 0.000 description 1
- HXCILVUBKWANLN-UHFFFAOYSA-N brilliant green cation Chemical compound C1=CC(N(CC)CC)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](CC)CC)C=C1 HXCILVUBKWANLN-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000004565 granule cell Anatomy 0.000 description 1
- 235000013882 gravy Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- HPQYKCJIWQFJMS-UHFFFAOYSA-L tetrathionate(2-) Chemical compound [O-]S(=O)(=O)SSS([O-])(=O)=O HPQYKCJIWQFJMS-UHFFFAOYSA-L 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 239000001974 tryptic soy broth Substances 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- 230000005570 vertical transmission Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- CZPRKINNVBONSF-UHFFFAOYSA-M zinc;dioxido(oxo)phosphanium Chemical compound [Zn+2].[O-][P+]([O-])=O CZPRKINNVBONSF-UHFFFAOYSA-M 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/42—Salmonella
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/879—Salmonella
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Environmental Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Animal Husbandry (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.家禽種において弱毒化生菌ワクチンとして使用するための微生物のヘテロ フィル適合化菌株を製造する方法であって、しかも、 a)該家禽種のメンバーから得られたヘテロフィルの第1の集団と共に野生型微 生物をインキュベートし、ヘテロフィル内在化微生物および細胞外微生物を含有 するサンプルを調製する工程と、 b)該ヘテロフィル内在化微生物の実質的に純粋なクローンを単離する工程と 、 c)該家禽種の該メンバーから得られたヘテロフィルの第2の集団と共に該クロ ーンからの微生物をインキュベートし、次の継代のヘテロフィル内在化微生物お よび次の継代の細胞外微生物を形成する工程と、 d)工程(b)および(c)を少なくとも3回目の継代まで繰り返し行う工程と、 e)該少なくとも3回目の継代から得れた該ヘテロフィル内在化微生物の実質的 に純粋なクローンを単離し、ヘテロフィル適合化菌株を得る工程と、を含む前記 方法。 2.前記工程(b)および(c)を少なくとも5回目の継代まで繰り返し行う請 求項1記載の方法。 3.前記ヘテロフィル適合化菌株がアルギニンヒドロラーゼ陰性である請求項 1記載の方法。 4.前記微生物がサルモネラ属のメンバーである請求項1記載の方法。 5.前記サルモネラ属の前記メンバーがSalmonella enteritidisである請求項 4記載の方法。 6.前記家禽種の前記メンバーが産卵鶏である請求項1記載の方法。 7.前記工程(b)および(e)の各単離工程が、抗生物質と共に前記ヘテロフ ィルをインキュベートする工程と、該ヘテロフィルを洗浄して該抗生物質を除去 する工程と、該ヘテロフィルを破砕する工程と、を含む請求項1記載の方法。 8.前記抗生物質と共にインキュベートする前記工程が、2種以上の抗生物質 と共に順次インキュベーションを行う工程を含む請求項7記載の方法。 9.前記抗生物質が、カナマイシンおよびゲンタマイシンから成る群より選ば れる請求項7または8記載の方法。 10.微生物の家禽ヘテロフィル適合化菌株の調製物を前記家禽に投与する工 程を含む、家禽へのワクチン接種方法。 11.前記微生物がサルモネラ属のメンバーである請求項10記載の方法。 12.前記メンバーがSalmonella enteritidisである請求項11記載の方法。 13.前記投与が経口投与である請求項10記載の方法。 14.コレラトキシンを前記家禽に与える工程を更に含む請求項10記載の方 法。 15.微生物の実質的に純粋な家禽ヘテロフィル適合化菌株。 16.微生物の前記菌株がサルモネラ属のメンバーである請求項15記載の菌 株。 17.前記メンバーがSalmonella enteritidisである請求項16記載の菌株。 18.前記ヘテロフィル適合化菌株がアルギニンヒドロラーゼ陰性である請求 項15記載の菌株。 19.微生物の実質的に純粋な家禽ヘテロフィル適合化菌株の調製物を含んで なる家禽用弱毒化生菌ワクチン。 20.微生物の前記菌株がサルモネラ属のメンバーである請求項19記載のワ クチン。 21.前記メンバーがSalmonella enteritidisである請求項20記載のワクチ ン。 22.コレラトキシンを更に含んでなる請求項19記載のワクチン。 23.前記ヘテロフィル適合化菌株がアルギニンヒドロラーゼ陰性である請求 項19記載のワクチン。 24.前記菌株がATCC受託番号 を有するSETK499である請求項19記 載のワクチン。 25.前記菌株がATCC受託番号55770を有するSETK598である請求項19記載の ワクチン。 26.前記ワクチンが経口投与に適している請求項19記載のワクチン。 27.微生物の家禽ヘテロフィル適合化菌株を含んでなる家禽メンバー。 28.前記微生物がサルモネラ属のメンバーである請求項27記載の家禽メン バー。 29.前記メンバーがSalmonella enteritidisである請求項28記載の家禽メ ンバー。 30.請求項27記載の家禽メンバーから卵を得る工程を含む、家禽から卵を 得る方法。 31.請求項27記載の家禽メンバーから家禽の身体部分を得る工程を含む、 家禽の身体部分を得る方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US964495P | 1995-12-19 | 1995-12-19 | |
US60/009,644 | 1995-12-19 | ||
PCT/US1996/020555 WO1997022688A1 (en) | 1995-12-19 | 1996-12-18 | Heterophil-adapted poultry vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2000502257A true JP2000502257A (ja) | 2000-02-29 |
Family
ID=21738900
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9523045A Ceased JP2000502257A (ja) | 1995-12-19 | 1996-12-18 | ヘテロフィル適合化家禽用ワクチン |
Country Status (5)
Country | Link |
---|---|
US (2) | US6120774A (ja) |
EP (1) | EP0876476A4 (ja) |
JP (1) | JP2000502257A (ja) |
BR (1) | BR9612090A (ja) |
WO (1) | WO1997022688A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20010555A1 (it) * | 2001-03-16 | 2002-09-16 | Fatro Spa | Ceppo attenuato di salmonella gallinarum-pullorum e vaccino che lo contiene |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI59925C (fi) * | 1980-01-11 | 1981-11-10 | Esko Viljo Nurmi | Foerfarande foer framstaellning av ett bakteriepreparat anvaendbart foer foerhindrande av salmonellainfektion hos fjaederfae |
AU554781B2 (en) * | 1982-12-30 | 1986-09-04 | Vsesojuzny Gosudarstvenny Nauchno-Kontrolny Institut Veterinarnykh Preparatov And Vsesojuzny Nauchno- Issledovatelsky Veterinarny Institut Ptitsvodstva | Live salmonella typhi-murium vaccine |
US5387744A (en) * | 1987-06-04 | 1995-02-07 | Washington University | Avirulent microbes and uses therefor: Salmonella typhi |
CA2094515C (en) * | 1990-11-01 | 1998-09-01 | Theodore T. Kramer | Bacterial attenuation method and vaccine |
US5356797A (en) * | 1991-11-15 | 1994-10-18 | Board Of Regents, The University Of Texas | Membrane expression of heterologous genes |
MX9301706A (es) * | 1992-04-13 | 1994-05-31 | Oravax Inc | Composicion de vacuna para el tratamiento de la infeccion por helicobacter. |
DE4333742A1 (de) * | 1993-10-04 | 1995-04-06 | Klaus Prof Dr Linde | Lebendimpfstoff mit erhöhter Stabilität |
JPH07206705A (ja) * | 1993-11-03 | 1995-08-08 | American Cyanamid Co | 生インオボ(in ovo)ワクチン |
-
1996
- 1996-12-18 JP JP9523045A patent/JP2000502257A/ja not_active Ceased
- 1996-12-18 WO PCT/US1996/020555 patent/WO1997022688A1/en not_active Application Discontinuation
- 1996-12-18 EP EP96945793A patent/EP0876476A4/en not_active Withdrawn
- 1996-12-18 BR BR9612090-8A patent/BR9612090A/pt not_active Application Discontinuation
-
1997
- 1997-02-14 US US08/801,722 patent/US6120774A/en not_active Expired - Lifetime
-
2000
- 2000-05-23 US US09/576,986 patent/US6376228B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US6120774A (en) | 2000-09-19 |
BR9612090A (pt) | 1999-12-28 |
EP0876476A4 (en) | 2001-04-18 |
WO1997022688A1 (en) | 1997-06-26 |
EP0876476A1 (en) | 1998-11-11 |
US6376228B1 (en) | 2002-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gast et al. | Salmonella infections | |
Shivaprasad et al. | Pullorum disease and fowl typhoid | |
Barrow | Salmonella control—past, present and future | |
EP1663302B1 (en) | Method for vaccination of poultry by bacteriophage lysate | |
CN101144062B (zh) | 一种干酪乳杆菌菌株及其制品在禽类免疫中的应用 | |
CN111254121B (zh) | 一种沙门氏菌噬菌体及在防治沙门氏菌感染的疾病的药物中的应用 | |
CN113583972A (zh) | 一株可降低抗生素耐药性的大肠杆菌噬菌体及其应用 | |
EP3160224B1 (en) | In ovo delivery of probiotic cultures | |
Marsden et al. | Potency testing of a live, genetically attenuated vaccine for salmonids | |
Dibb-Fuller et al. | Contribution of fimbriae and flagella of Salmonella enteritidis to colonization and invasion of chicks | |
US11844818B2 (en) | Aeromonas hydrophila bacteriophage Aer-HYP-3 and use thereof for inhibiting growth of Aeromonas hydrophila bacteria | |
Salehi et al. | Characterization of Escherichia coli isolates from commercial layer hens with salpingitis | |
CN116286671A (zh) | 一株沙门氏菌噬菌体sp8、噬菌体组合物及其应用 | |
Knivett et al. | The evaluation of a live Salmonella vaccine in mice and chickens | |
JP2838098B2 (ja) | サルモネラ菌生ワクチン | |
KR101830900B1 (ko) | 신규한 조류 병원성 대장균 특이 박테리오파지 ec13 및 이를 포함하는 항균 조성물 | |
JP2000502257A (ja) | ヘテロフィル適合化家禽用ワクチン | |
US7988978B2 (en) | Composition and method for controlling intestinal pathogenic organisms | |
US7935355B2 (en) | Composition and method for controlling intestinal pathogenic organisms | |
KR102673134B1 (ko) | 박테리오파지를 포함하는 살모넬라 엔테리티디스 증식 억제용 조성물 | |
Barbour et al. | Immunopotentiation of a developed Salmonella enterica serotype enteritidis vaccine by thymulin and zinc in meat chicken breeders | |
CN113755451B (zh) | 一株大肠杆菌噬菌体gn6及其应用 | |
CN113430176B (zh) | 一株稳定高效的烈性沙门氏菌噬菌体rdp-sa-21004及其应用 | |
Sen et al. | Immunogenicity and duration of immunity of the polyvalent vaccine against chicken salmonellosis | |
KR20230164829A (ko) | 박테리오파지를 포함하는 살모넬라 엔테리티디스 증식 억제용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040330 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20040319 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040630 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040816 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040930 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20051018 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20060306 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060411 |